12/23
04:14 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/22
12:23 pm
zbio
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says [Yahoo! Finance]
Medium
Report
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says [Yahoo! Finance]
12/22
08:42 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
12/19
04:23 pm
zbio
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/19
04:15 pm
zbio
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/16
04:43 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
08:43 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/15
08:17 am
zbio
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus [Yahoo! Finance]
High
Report
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus [Yahoo! Finance]
12/15
07:05 am
zbio
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
High
Report
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
12/15
04:23 am
zbio
Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating [Seeking Alpha]
High
Report
Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating [Seeking Alpha]
12/4
04:39 pm
zbio
Top SA Quant rated small-cap stocks as Russell 2000 notches a record close [Seeking Alpha]
Medium
Report
Top SA Quant rated small-cap stocks as Russell 2000 notches a record close [Seeking Alpha]
11/26
08:19 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $55.00 price target on the stock.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $55.00 price target on the stock.
11/20
09:14 am
zbio
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
Medium
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
11/13
08:28 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.
11/12
09:57 am
zbio
Zenas BioPharma, Inc. GAAP EPS of -$1.22 [Seeking Alpha]
Low
Report
Zenas BioPharma, Inc. GAAP EPS of -$1.22 [Seeking Alpha]
11/12
07:05 am
zbio
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/11
07:05 am
zbio
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Medium
Report
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
11/8
01:18 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at
Wall Street Ze
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at
Wall Street Ze
10/30
03:59 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
10/30
12:32 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/28
10:59 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/28
08:09 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at HC Wainwright from $30.00 to $44.00. They now have a "buy" rating on the stock.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at HC Wainwright from $30.00 to $44.00. They now have a "buy" rating on the stock.
10/27
11:08 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $40.00.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $40.00.
10/27
03:59 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
10/27
03:59 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.